Mainz Biomed secures $6M private placement, names David Lazar Chairman; pivots to pancreatic cancer

Quantum Cyber N.V.

First tranche of $3M closed Feb 13; second $3M expected after shareholder approval by April 15, 2026.
Preferred shares convertible into up to 95%+ of fully diluted shares; Lazar appointed Chairman and gets board nomination rights.
Company to focus on U.S. pancreatic cancer detection, evaluate sale of colorectal assets, wind down German sub.
Settlement agreements with officers/directors require ~$1.9M aggregate payments upon final closing.

item 1.01item 5.02item 3.02item 3.03item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.